NVAXNovavax, Inc.
$12.74+46% 1Y
$12.74
$6.2252 weeks$12.74
Latest close: a new 52-week highOct 9, 2026what changed →
NVAX in its own filings
NVAX's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
596
Events found in the filings · across 1,643 filings · the record starts in 1996
- Hard flags
- 3
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 25, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Restatement admitted (non-reliance)historical
- 2011-03-17
- Change in certifying accountant4 occurrences
- 2014-05-07
- Late periodic report4 occurrences
- 2020-11-10
- Delisting notice / listing-rule failure3 occurrences
- 2019-04-12
- Material impairmentpast_year
- 2025-10-22
- SEC comment-letter activity44 occurrences
- 2024-05-14
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jan 20, 2026License Agreement On January 15, 2026, (the “Effective Date”), Novavax, Inc. (the “Company”) entered into a License and Option Agreement (the “License and Option Agreement”) with Pfizer Inc. (“Pfizer”), collectively (the “Parties”)Material agreement entered · Form 8-K
- Jan 12, 2026© 2026 NOVAVAX. All rights reserved.Earnings release · press release
- Nov 4, 2025On November 3, 2025 the Federal Drug Administration approved the transfer application to change the holder of the marketing authorization for Nuvaxovid ™ from Novavax to Sanofi Pasteur Inc. (“Sanofi”)Regulation FD disclosure · Form 8-K
- Oct 22, 2025On October 17, 2025, Novavax, Inc. (the “Company”) entered into an assignment of the Company’s 700 Quince Orchard Road, Gaithersburg, MD facility with AstraZeneca Pharmaceuticals LP (“AstraZeneca”)Material agreement entered · Form 8-K
- Oct 7, 2025On October 1, 2025 the European Commission approved the transfer application to change the holder of the marketing authorization for Nuvaxovid ™ from the Company’s wholly owned subsidiary, Novavax CZ, to Sanofi Winthrop Industrie.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks